The greatest quality-adjusted survival gain with NIVO + chemo was observed among patients with MSI-H (10.5 [95% CI 4.3, 16.7] months), followed by those with tumor cell PD-L1 ≥ 1% (5.3 [95% CI 2.7, 8] months). This evidence concerns the gene CD274 and neoplasm.